Lumeda Revenue and Competitors
Estimated Revenue & Valuation
- Lumeda's estimated annual revenue is currently $852.5k per year.
- Lumeda's estimated revenue per employee is $77,500
- Lumeda's total funding is $7.4M.
Employee Data
- Lumeda has 11 Employees.
- Lumeda grew their employee count by -39% last year.
Lumeda's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & VP Engineering | Reveal Email/Phone |
2 | Founder & VP Business Development | Reveal Email/Phone |
3 | Senior Quality Manager | Reveal Email/Phone |
4 | Senior Electrical Engineer | Reveal Email/Phone |
Lumeda Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.2M | 1 | 0% | N/A | N/A |
#2 | $3.3M | 21 | -25% | N/A | N/A |
#3 | $9.8M | 81 | -10% | N/A | N/A |
#4 | $1.7M | 11 | 450% | N/A | N/A |
#5 | $20.3M | 131 | -23% | N/A | N/A |
#6 | $5.4M | 35 | -22% | N/A | N/A |
#7 | $2M | 13 | 44% | N/A | N/A |
#8 | $2.8M | 18 | 20% | N/A | N/A |
#9 | $0.3M | 4 | 0% | N/A | N/A |
#10 | $3.6M | 23 | -12% | N/A | N/A |
What Is Lumeda?
Lumeda Inc. is a medical technology company advancing photodynamic therapy (PDT) as an adjuvant treatment for patients with non-small cell lung cancer (NSCLC) and other thoracic malignancies. Lumeda’s breakthrough light dosimetry product called DigiLum™ is designed to activate a photosensitizer drug and deliver PDT to reduce the recurrence of cancer and enhance antitumor immunity. DigiLum™ applies advanced photonics and proprietary Artificial Intelligence (AI) software to enable thoracic surgeons to control dosimetry, reduce treatment time and capture data for future treatment planning.
keywords:N/A$7.4M
Total Funding
11
Number of Employees
$852.5k
Revenue (est)
-39%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.9M | 12 | 50% | N/A |
#2 | $1.9M | 12 | 20% | N/A |
#3 | $1.5M | 17 | -6% | N/A |
#4 | $3M | 17 | 42% | N/A |
#5 | $6.5M | 30 | -6% | N/A |